Harbin Pharmaceutical Group Co Ltd
600664
Company Profile
Business description
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
Contact
Xi'an Street West
People 's Development Zone Baoan Road South
Heilongjiang Province
Harbin150018
CHNT: +86 45151870077
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
10,180
Stocks News & Analysis
stocks
Market Minute: RBA cuts rates again, US CPI data released
This week, the RBA cut rates after a surprise hold in July; CBA reported earnings ; US inflation data came out, showing its highest reading since February.
stocks
Is the market still overlooking Alibaba’s AI potential?
Despite a 40% share price rally this year, investors could still be underestimating Alibaba’s cloud growth prospects.
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
A round up of notable stories and reactions as ASX earnings season gathers steam.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,212.10 | 63.00 | 0.69% |
CAC 40 | 7,923.45 | 53.11 | 0.67% |
DAX 40 | 24,359.30 | 18.20 | -0.07% |
Dow JONES (US) | 45,019.66 | 108.40 | 0.24% |
FTSE 100 | 9,138.90 | 38.34 | -0.42% |
HKSE | 25,270.07 | 249.25 | -0.98% |
NASDAQ | 21,637.36 | 73.31 | -0.34% |
Nikkei 225 | 43,378.31 | 729.05 | 1.71% |
NZX 50 Index | 12,889.38 | 55.30 | 0.43% |
S&P 500 | 6,457.73 | 10.81 | -0.17% |
S&P/ASX 200 | 8,938.60 | 64.80 | 0.73% |
SSE Composite Index | 3,696.77 | 30.33 | 0.83% |